



If you would like to share news or information with our readers, please send the unique stories, business

news organization events, and school news to us including your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com or contact

John Robbins 281-965-6390
Jun Gai 281-498-4310

Pandemic Cancels Texas African Business Summit

Southern DAILY

Southern Daily News is published by Southern News Group Daily

Sunday, January 31 2021

Inside C2

Analysis: Robinhood and Reddit protected from lawsuits by user agreement, Congress



(Reuters) - Robinhood Markets Inc's user agreement is likely to protect the brokerage app from a barrage of lawsuits filed by customers after it blocked a frenzied trading rally in companies such as GameStop Corp that was fueled on social media forums.

FILE PHOTO: Trading information for GameStop is displayed on the Robinhood App as another screen displays the Robinhood logo in this photo illustration January 29, 2021. REUTERS/Brendan McDermid/Illustration/File Photo

The owners of internet platforms where much of the discussion took place are likewise shielded from liability for users' activity under a 25-year-old law known as Section 230.

At least a dozen proposed class action lawsuits accuse Robinhood of breaching its contract with customers when it restricted trading on Thursday.

Robinhood's users were at the center of this week's wild rally in a handful of stocks that had been heavily shorted by hedge funds and championed by individual investors in online

chatrooms including Reddit's WallStreetBets.

The lawsuits, brought in federal court, allege that the Menlo Park, California-based company breached its contractual obligation as a regulated broker to execute orders promptly and effectively.

However, Robinhood is not legally bound to carry out every trade and the lawsuits will not succeed without evidence the company restricted trading for an improper reason, such as to favor certain investors, according to several legal experts.

The user agreement on Robinhood's website says it "may at any time, in its sole discretion and without prior notice to Me, prohibit or restrict My ability to trade securities."

Adam Pritchard, a professor at the University of Michigan Law School, said the lawsuits are very unlikely to gain traction.

"The contract says they can do it," Pritchard said of the company's decision to restrict trading. "That seems to be a big stumbling block to the breach of contract claim."

Robinhood did not immediately respond to a request for comment.

The popular commission-free trading platform had branded itself as an app to empower retail investors to take on Wall Street and democratize finance, and the trade restrictions sparked an uproar and claims of betrayal on social media.

Robinhood said the restrictions were necessary to comply with regulatory capital requirements and clearinghouse deposits, which it said fluctuate with volatility.

SUITS AGAINST BROKERS

The lawsuits allege the restrictions benefited large funds that were allegedly invested in or allied with Robinhood.

But the customers are unlikely to clear preliminary court hurdles to get to the point where they can demand documents and depositions to investigate Robinhood's actions, said Ann Lipton, a professor at Tulane University Law School.

She said attempts to sue brokers for mishandling customer accounts have generally been unsuccessful due to limits that federal securities law places on the filing of class actions. For example, a federal judge in 2019 dismissed a proposed class action against TD Ameritrade Holding Corp for allegedly mismanaging a tax feature of certain accounts.

Billionaire Steve Cohen quits Twitter, citing threats in GameStop uproar

BOSTON (Reuters) - Billionaire investor Steve Cohen, seen by small investors as an enemy in the GameStop stock drama this week, deleted his Twitter account because of what he said were threats against him and his family, a spokeswoman said on Saturday.

"I'm going to take a break for now," Cohen said on Twitter late on Friday, citing "personal threats." His account no longer appeared on Saturday, and a spokeswoman for Cohen's Point72 Asset Management confirmed it was closed.

The small investors, connected on social media, mobilized to take on institutional short sellers of GameStop and other shares, sparking a short squeeze that sent those stock prices surging. The details of Cohen's holdings were not disclosed, so it was unclear if he was a short seller.

However, Cohen's Point72 and Citadel LLC gave a capital infusion to Melvin Capital, a fund that held a large short position in GameStop, enabling it to close out that position with a large loss and survive.



Cohen, who previously used Twitter largely to engage with fans of the New York Mets baseball team after he bought a majority stake last year, was among fund managers who received threats as the GameStop saga unfolded.

On Thursday, Cohen got into a heated debate with blogger Dave Portnoy, who founded the sports and pop culture blog Barstool Sports. Cohen, worth roughly \$14 billion, tweeted, "Hey Dave, What's your beef with me. I'm just trying to make a living just like you."

Point72 lost between 10% and 15% in value since the start of the year to the middle of the week, people familiar with the numbers said.



www.afnb.com

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available on the App Store

Get it on Google play

Available

WEA LEE'S

GLOBAL NOTES

01/30/2021

CORONAVIRUS DIARY

Wealee@scdaily.com

The One Shot Vaccine Is Coming

Johnson & Johnson is the only major drug company developing a one-shot vaccine for COVID. It is a shot that will provide strong protection and potentially offer another powerful tool to fight the worldwide crisis.

Johnson & Johnson became the fiftieth company supported by the U.S. government to develop an effective vaccine in less than one year and the only one that will need only one dose. It is very important that the new vaccine gets approved as soon as possible to reduce the burden of the crisis around the world.

White House officials have been counting on the Johnson & Johnson vaccine to ease the shortfall of supply.

When the nation is screaming to get more vaccines, this new product will not just be for our own use. It also will help more people around the world in the future.

Today, of the total world population, only a few rich countries are in control of the vaccine. We still have most people without the vaccine. When we look at the



measure to pass the relief bill. Unless we can take care of the current pandemic, our economy will still suffer.

If Johnson & Johnson can deliver the vaccine quickly enough to United States, it might be able to drive down the number of new cases before the new variants make things worse.

current pandemic, unless we can vaccinate the majority of the people, we just cannot stop the crisis.

The Biden administration is doing their best now in many ways. We want to urge the Congress to take the dramatic

We really want to salute all the scientists for their contribution for making another new vaccine, not just to save our nation, but for the rest of the world as well.




Stay Home!

BUSINESS

Wear Mask!

One Year Of The Coronavirus



The Countries With The Most COVID-19 Cases

Total number of confirmed COVID-19 cases, by country*



* As of 27 January 2021 at 11:30 GMT

Source: Johns Hopkins University

Total Cases

Total Worldwide	Cases	Recovered	Deaths
100M	55.4M	2.16M	2,160,000
100,000,000	55,400,000	2,160,000	2,160,000
Location	Cases	Recovered	Deaths
United States	25.6M	429K	429,000
	25,600,000	429,000	429,000
	+156K	+4,101	+4,101
India	10.7M	10.4M	154K
	10,700,000	10,400,000	154,000
	+11,666	+14,301	+123
Brazil	9M	7.96M	220K
	9,000,000	7,960,000	220,000
	+63,520	+67,886	+1,283
Russia	3.73M	3.17M	69,971
	3,730,000	3,170,000	69,971
	+17,464	+27,440	+580
United Kingdom	3.72M	102K	102,000
	3,720,000	102,000	102,000
	+25,308	+1,725	+1,725

"+" shows new cases reported yesterday · Updated less than 6 hours ago · Sources: Wikipedia


Compiled And Edited By John T. Robbins, Southern Daily Editor

One year ago today, a novel coronavirus was barely beginning to catch the public's eye. There were just over 2,000 confirmed cases worldwide, mostly in China, and five cases in the U.S.

The big picture: The sea of red (dark color) says it all. Today, there have been over 100 million cases worldwide, led by the U.S. with 25 million.

Coronavirus Cases Fall In 41 U.S. States

Change in new COVID-19 cases in the past week



Data: The COVID Tracking Project, state

health departments; Map: Andrew Witherpoon/Axios

New coronavirus infections fell by 16% over the past week in the U.S. — the third straight week of significant improvement.

But the U.S. is still averaging roughly 165,000 new cases per day, meaning the virus is still spreading largely unchecked. And the rise of more contagious variants will ensure that Americans' risk remains high.

Details: In 41 states, the average number of new daily cases was lower over the past week than the week before. No states got worse.

• Nationwide, new cases are now at about the same level they were at in mid-December — down from their peak, but still a lot.

What's next: If Americans can accelerate this progress, we'll reduce the number of people who die before vaccines become universally available.

• But that will be a challenge, given the country's track record and the continued spread of more easily transmissible variants.

Coronavirus Dashboard



Illustration: Eniola Odetunde/Axios

1. **Health:** One year of the coronavirus — Bill and Melinda Gates warn of "immunity inequality" — Communities of color are falling behind in America's vaccine effort.

2. **Vaccine:** Vaccine hesitancy is decreasing in the U.S.

3. **Politics:** Biden admin to boost COVID vaccine delivery to states for at least 3 weeks — Hundreds of Biden staffers receive COVID vaccine — Axios-Ipsos poll: Trust in federal COVID-19 response surges.

4. **Business:** Bankruptcy filings hit decade-high last year.

5. **World:** U.K. surpasses 100,000 COVID-19 deaths — 44% of Israelis have already received at least one vaccine dose.

6. **Sports:** Europe's 20 richest soccer clubs report 12% revenue hit due to coronavirus — Pandemic has cost the NCAA \$600 million — CDC looks at lessons learned from NFL's testing and contact tracing.

Cases:

1. **Global:** Total confirmed cases as of 12 p.m. ET Wednesday: 100,418,923 — Total deaths: 2,161,547 — Total recoveries: 55,560,956 (no longer includes U.S. recoveries as of Dec. 15).

2. **U.S.:** Total confirmed cases as of 12 p.m. ET Wednesday: 25,450,135 — Total deaths: 425,406 — Total tests: 295,369,233.

Sunday, January 31 2021

Southern
DAILY Make
Today
Different

Editor's Choice



A patient suffering from COVID-19 breathes with a non-rebreather mask in an isolation room at a hospital in Bogor, Indonesia January 26, 2021. REUTERS/Willy Kurniawan



Health workers are seen in protective gear inside a locked down portion of the Jordan residential area to contain a new outbreak of the coronavirus in Hong Kong, China January 23, 2021. The government found 13 confirmed cases after testing about 7,000 residents in the densely populated neighborhood. REUTERS/Tyrone Siu



Healthcare workers line up before receiving the first dose of the Sinovac's CoronaVac coronavirus vaccine in the Positivo event center at the Barigui Park in Curitiba, Brazil. REUTERS/Rodolfo Buhrer



President Joe Biden speaks about the fight to contain the coronavirus disease (COVID-19) pandemic, in front of a portrait of Abraham Lincoln at the White House in Washington, January 26, 2021. Biden has proposed \$1.9 trillion in new pandemic relief,..




Sister Jenthia and Dr. Angela Branche hand out a coronavirus survival kit to Natalie Hall as part of a door-to-door outreach program to the Black community to increase vaccine trial participation in Rochester, New York. Their efforts rely heavily on grassroots partners such as churches and health centers, and aim to topple long-standing barriers that keep minorities from participating in clinical trials. The coronavirus kills Black people at three times the rate it kills whites. Picture taken October 17, 2020. REUTERS/Lindsay DeDario



Reena Jani, 34, a health worker, receives the coronavirus vaccine developed by Oxford/AstraZeneca at Mathalput Community Health Centre in Koraput, India. Jani's name was on a list of 100 health workers at Mathalput Community Health Centre, making her one of the first Indians to be inoculated earlier this month, as the country rolls out a vaccination program the government calls the world's biggest. But she had heard rumors of serious side effects and worried about what would happen were she to get ill. "I was frightened because of my son and daughters. If something happens to me, what will they do?" Jani said. Picture taken January 16, 2021.



Family members carry the coffin of a man who died of the coronavirus at a cemetery in Lima, Peru January 27, 2021. REUTERS/Angela Ponce



House impeachment managers led by Cheryl Johnson, clerk of the House of Representatives, and Timothy Blodgett, acting sergeant at arms of the House, return to the House side after delivering the article of impeachment against former President Donald Trump to the Senate for trial on accusations of inciting the deadly January

What Covid Treatments Are Working And What More Is On The Horizon?



New data from a large U.K. trial added to evidence indicating plasma may not make a difference in treating Covid-19. (Photo/Alex Edelman/AFP via Getty Images)

Key Point

Some therapies that faced early questions are regaining their promise as we learn more. Others aren't, but it's important news either way.

Compiled And Edited By John T. Robbins, Southern Daily Editor

The arrival of Covid-19 vaccines has put the focus of the pandemic fight on inoculating as many people as quickly as possible. But outbreaks are still raging worldwide, with thousands of new infections every day and health systems under pressure to care for the sick, a reality that will continue for some time. Vaccine timelines also keep getting more and more stretched. With that in mind, it's a good time to take stock of where we are in treating the disease. The short answer is, there's progress but it's mixed.

For months, Gilead Sciences Inc.'s **remdesivir** and the generic steroid **dexamethasone** have been used on the front lines after being shown to reduce hospital stays and improve recovery speeds. Now, as we learn more about Covid-19, more treatments — including some that at first drew skepticism from physicians and scientists — are proving effective in certain circumstances. Others, such as convalescent plasma, are not. Let's take a look:

"Toc": Two arthritis drugs that previously failed in treating Covid-19 — Roche Holding AG's **tocilizumab** and Sanofi-Regeneron Pharmaceuticals Inc.'s **sarilumab** — are now showing a meaningful effect in helping reduce the burden of

disease in some patients. It seems that when the drugs are used is key. The latest data comes from a trial involving patients who were treated within 24 hours of needing hospital care in an intensive care unit. The drugs reduced mortality, suggesting that seven or eight lives would be saved for each 100 people treated.



The hope is that this data will be corroborated in the U.K.'s much larger and pioneering Recovery trial now underway, with more than 3,000 of the 28,000 and rising participants treated with "toc." This will provide the most concrete data behind the drug and will potentially enable global approvals beyond Britain. **"Bam-bam":** Next up are new drugs developed by Eli Lilly & Co. and Regeneron, part of a promising group of therapies called monoclonal antibodies that mimic the body's

response to infection. Lilly's **bamlanivimab**, affectionately known as "bam-bam," was the first to gain emergency use authorization by the Food and Drug Administration. Both Lilly's and Regeneron's treatment have now been cleared for high-risk patients to help prevent hospitalization. One obstacle for adoption of these drugs has been the logistics of administering them — they need to be delivered using specialized infusion equipment. This difficulty was compounded in bam-bam's case with a confusing efficacy story and lukewarm comments about it in the Covid-19 treatment guidelines from the National Institutes of Health, resulting in doses piling up on hospital shelves. This situation may be about to change, though, given an early read from a 2,000-patient Mayo Clinic study in which the use of bam-bam was shown to reduce hospitalizations and emergency room visits by 70%.



There are also indications of a reduction in mortality. When data from this study is published, it is likely to drive increased interest in the use of bam-bam, and possibly Regeneron's antibody treatment, too. I do still remain cautious about the broad use of these drugs because of the risk they may hasten development of resistant mutations in the virus, which may, though unlikely, also impact vaccine-induced immunity.

Plasma: Convalescent plasma, a source of hope in the early days of the pandemic, has had a lot of subsequent failures and questions about its use. While not a drug per se, it is supposed to work in a similar way as monoclonal antibodies by giving patients ready-made immunity in a bottle in the form of plasma from recovered patients that is full of antibodies to the virus. The problem with previous attempts in showing a benefit from this approach was a lack of standardization and its use at the wrong time. Then recent data from a trial in Argentina raised hopes that if you use plasma with high amounts of antibodies early enough, when the infection itself is still active, it does make a difference. Unfortunately, there's since been another setback, and this time a very serious one. The

U.K.'s aforementioned Recovery trial has been comparing Regeneron's antibody treatment and convalescent plasma to standard care without those treatments in a very large patient group, making the data and its statistical analysis very robust.



Findings released Friday from the trial showed no difference in the mortality of those receiving plasma and those on placebo. We still need to see the data in published form to be able to judge if there were any other potential explanations for the outcome. But if the result is unequivocal, it at least means there will be no more time and money wasted treating patients with an ineffective therapy that carries some risks. In a way, the negative outcome is still a step forward in sharpening treatments of Covid-19.

Once A Relic Of Medical History, Radiation Emerges As An Intriguing — And Controversial — Treatment For Covid-19

The idea of low-dose radiation as therapy had long been dismissed in favor of more modern treatments. That all changed when Covid-19 snowballed into a crisis, fueling fresh interest in anything that might ease the devastating cases of pneumonia in some patients. At least 52,000 of the more than 135,000 deaths due to Covid-19 in the U.S. have involved pneumonia, according to federal health data.

There are currently at least a dozen trials worldwide testing low-dose radiation therapy, or LDRT, as a treatment for pneumonia related to Covid-19, some spurred by the same historical data Calabrese and colleagues scoured years ago. The theory: Targeted radiation to the lungs will halt the out-of-control inflammation responsible for the devastating pneumonia that bookends the course of some Covid-19 patients. **General Photographic Agency/Getty Images** But the revived interest in radiotherapy has sparked a debate among physicians and researchers, who are divided on whether the idea is even ready for test-driving in clinical trials. With little known about the way LDRT works on inflamed lungs, some experts say it might

exacerbate respiratory damage, while introducing the additional risk of cancer. Others say patients participating in the trials may suffer by missing out on more promising treatments.

On the other side, though, are experts who say there's a clear and urgent need for Covid-19 treatments that work, particularly for cases that become severe. Antibiotics can help treat cases of pneumonia from bacterial infections, but not those caused by viruses. Those experts argue compelling historical data gives LDRT a promising head start.

"It seems to be such an almost emotional topic," said Dörthe Schaeue, a radiation oncologist at UCLA, on the debate raging over LDRT. "You get two extremes on the spectrum and the truth is probably somewhere in the middle, where you have to consider all the pluses and minuses."



The new wave of low-dose radiation trials are registered at academic centers and hospitals around the world, including in Italy, Spain, Iran, India, and the U.S. The studies are recruiting anywhere from five to 106 Covid-19 patients with pneumonia, and half require participants to be at least 40 years of age.

Arnab Chakravarti, chair of Ohio State's radiation and oncology department, is spearheading two of the four LDRT trials in the U.S. The first trial, PREVENT, will enroll around 100 oxygen-dependent Covid-19 patients at up to 20 hospitals around the country. The second trial, VENTED, is limited to Ohio State, where it will recruit 24 critically-ill patients who require ventilator support. Unlike PREVENT, VENTED is open to participants as young as 18.

The end of the pandemic may be in sight, assuming we can control infections and the development of new variants, but it's still many months away. Fortunately, the more we learn, the better we know which treatments are helpful and how to use them. The arsenal is growing. We can use all the help we can get. (Courtesy Bloomberg.com and <https://www.statnews.com/>)

Why is my MRI normal and I still hurt?

Go to www.thepaindiagnosistest.com to find out why

腊八节马云现身，理由给100分



马云线上发言全文

各位老师、各位校长，各位理事，还有关心乡村教育的朋友们，大家上午好！

首先祝贺100位获奖的老师。每年腊八节，是我们约定的日子，过去五年，每年的这一天，我们都在三亚举办颁奖仪式，感谢老师、致敬老师。今年因为疫情的原因不能在三亚见面，但是我们的约定不变，对老师的致敬更不会缺席，今天我们大家虽然在天南海北，但是我们用视频连线的方式聚在一起，这是我们对100名获奖老师的敬意，也是对100名老师背后290万乡村教师的敬意。等疫情过去了，我们一定找时间把大家的三亚之旅补上，到那时我们再见面！

刚才老师们介绍了自己，其实在今天见到大家之前，我已经认识各位老师了。过去的半年，基金会的同事和志愿者们在全国各地的乡村走访，寻找，记录，在这个过程中，我陆续听到了很多你们的故事，像来自最南边的李伟老师，自创了一套“田园教学法”，带着孩子走进菜地，走进大自然学习；80后的摇滚青年顾亚老师，不但在贵州高原小学待下来，还把摇滚音乐带给孩子们；田金辉老师，用手机给学生们拍下上万张照片，让那些在外打工的父母们看见孩子的成长；李艳丽老师写山里孩子的故事，最后得了文学大奖……这些年关注乡村老师，我还有一个特别大的感受，乡村教育每天都在进步，这个背后离不开国家的投入，也离不开老师的坚守和付出。

中国有290万乡村老师，更多的老师，他们的付出可能一辈子都没有太多人知道。我一直觉得，乡村教师奖的评选过程不是我们在评选老师，而是老师在感召我们。基金会送给老师的，只是我们的一点点敬意；而老师们给予我们的，却是精神上的巨大启发。

这段时间，我和同事一直在学习和思考，我们更加坚定了全身心投入教育公益的想法。这不仅仅是因为我自己是老师出身，更重要的是，教育特别是乡村教育关系重大。今天，我们国家实现了全面脱贫，全面推进乡村振兴战略，进入新发展阶段，正在走向共同富裕。支持好、服务好乡村老师，做好教育部门的补充，更好地发展乡村教育，为乡村振兴、共同富裕而努力，我想这是我们这一代企业经营者的责任和担当。

我们相信，未来乡村生活一定会越来越美好，未来的乡村是蓝天白云下的现代化，有一天越来越多的年轻人会回到乡村。我会和老师们一起努力，也欢迎更多人加入进来，一起加油，乡村的教育提升一点，我们离共同富裕就会近一点。一起做好这件事，这就是我们今天说好的约定！

腊八节中午，“马云现身”的消息刷屏网络！

阿里集团内网快速发布了一篇帖子——《腊八节和老师们有个约定，定马老师来赴约了》，随后阿里系股价悉数拉升。

以此来看，虽然马云退休了，但他对阿里系的影响还是不容小觑。

腊八节马云就要现身？这是什么逻辑？

腊八节马云必须现身，因为有100名乡村教师等着他颁奖呢，背后更有中国290万乡村老师看着呢，马云岂能爽约？

我们知道，马云教师出身，纵使在执掌阿里期间，也从未放弃对教师职业的梦想，尤其关注乡村教师群体，还自称乡村教师代言人。

自2015年起，每年腊八节，他都要与100名优秀乡村教师相约三亚，举行盛大的“马云乡村教师奖颁奖典礼，连续五年雷打不动。

今年出现了一些小插曲，但还是等到了腊八节马云现身。

要知道，马云已经连续消失了70多天，此时他心系乡村教师，信守承诺，为了完成约定，突然现身。

如果不是因为疫情的影响，昨天腊八节马云现身。

日的三亚可能就是媒体聚焦的中心。

尽管疫情打乱了既定的节奏，但马云依然坚持完成了这次颁奖典礼，由线下改为线上，而他也准时出场，还发表了激动人心的讲话。

在视频连线时，他特别强调，等疫情过去了，一定找时间把大家的三亚之旅补上，到那时我们再见！

马云信守承诺，值得期待。

马云事件接近尾声

无独有偶，上周，一篇名为《马云现身了》的文章在朋友圈里疯传，说马云现身三亚打高尔夫，文章有图有真相，也写得有鼻子有眼。

马云就真的现身了！上次或许是为这次的现身预热，看看媒体舆论的反应。

为什么要观察舆论的反应？

这还得从10月24日，马云在上海滩炮轰巴塞尔协议是老年俱乐部，银行是当铺，中国金融没有系统说起，此番引发极大争议。

从此之后，马云再也没有公开露面，微博也停更了。期间的11月2日

，他以蚂蚁集团掌门的身份被四部委联合约谈，此后蚂蚁暂停上市。

马云从此在江湖消失，距昨日现身整整76天。期间也不断有消息传出，马云现身，最近的一次就在三亚打高尔夫。

这从侧面说明了

，外界对马云的关注度还是很高的，马云现身还是有群众基础的。

特别是他几十年如一日建立起的乡村教育理念，没有他的支持，很难执行下去。

这背后可是290万乡村教师的信任啊。

昨日腊八节，马云以教师的身份公开现身，说明他还未忘记初心。此次现身，基本宣告马云事件接近尾声。

乡村教育理念深入人心

作为中国大富豪，马云做教育是认真的。

他在此次视频讲话中提到，“更

好地发展乡村教育，为乡村振兴、

共同富裕而努力，我想这是我们这

一代企业经营者的责任和担当。”

他不仅找到了一个企业家应有的

担当和发力点，能够看透问题的

本质，好的教育应是教师先行，只

有教师好了，教育才会好。

多年来，他一直是这样践行的

，不仅捐款，还亲力亲为。

2015年，他发起“马云乡村教

师计划”，此后每年举办一届，每

届奖励100位一线优秀乡村教师，给

予连续三年总计10万/人的现金奖励

与专业发展机会。

颁奖典礼就是昨天——腊八节

，今年已经是第六届了，已资助了

600名优秀教师。

有了优秀的教师，也需要有优

秀的教育管理者，他要将校长变成

CEO，在2015年同时设立“马云乡

村校长奖”，为获奖校长提供50万

元的实践经费以及出国深造机会。

为了完善“乡村教育的三级火

箭”联动效应，2017年，他又设立

“马云乡村师范生计划”，以此培

养应届优秀师范毕业生成为乡村教

师。

设立这个计划的初衷是，他认

为，只有让最优秀的学生成为乡村老师，乡村教育才会强。

以“乡村师范生计划”吸引优秀人才加入乡村教育，产生大批优秀教师，然后从中择优选拔进入“乡村教师计划”，再从“乡村教师计划”中选出优秀校长入围“乡村校长奖”。

这样就可以形成正向循环，解决乡村教育中的师资力量问题，这或许就是马云的初心。

马云死磕教育

马云说过，“我这一辈子拿不掉的烙印就是老师。”

这一点从他人生的三个阶段都可以验证，无论身居何位，他从没有忘记自己是一位人民教师，30年来，初心不改。

1988年，他从杭州师范毕业，被分配到杭州电子工业学院教英语，时年24岁，在三尺讲台上他一干就是六年。

这是为他教育生涯的第一个阶段，教书他是认真的，不仅得到学生爱戴，更被评为杭州市优秀青年教师。

其后，因为接触到互联网的缘故，他觉得有比教书更重要的事要干，在1995年离职创业，但他给自己立下了一个“十年之约”，未来还会回归教育。

这是他教育生涯的第二个阶段，虽然没有直面讲台，但他在为创业者传道授业，为阿里培养了无数技术人才，让他们有施展才华的机会，比如王坚、程航，这些都是曾被人“嫌弃”的人。

此后，他又给自己立下了一个“十年之约”，必须直面教育，回归真正的三尺讲台，为一线教育做出应有的贡献。

这是他教育生涯的第三个阶段，这一次，他兑现了诺言，将自己的微博改为“乡村教师代言人”，落实了“三级火箭”教育计划。

30多年来，马云始终没有忘记自己是一名教师，也一直助力教育。

他曾将自己的退休计划特意选在教师节那天公布，高调宣布，其重心将回归教育老本行，2018年的教师节被称为史上最“高调”的教师节。

这都是他不忘初心的表现，经过一系列的舆论沉浮，相信马云看清楚了自己的责任和担当，既往不恋，纵情向前，从此没有马云的时代，更没有时代的马云，只有乡村教师“马老师”。



但我没在你们身上在你们眼中看到不容易



華美中醫學院

American College of Acupuncture & Oriental Medicine

- 美國高等教育院校評鑑會認准

- 美國中醫院校評鑑會認准

- 德州高等教育部認准頒授碩士學位

- 中醫專業碩士學位

- 綜合保健管理碩士學位

詢問有關本校\$10,000的獎學金的詳情

電話: 713-780-9777 網站: www.acaom.edu

請今天就申請!

- 中外中醫名流授課
- 中西醫學多元化教學
- 學科及臨床並重
- 全時或半時上課
- 日班或夜班課程

德州脊椎中心/復健科診所

Texas Spinal care 最新技術治療腰椎、頸椎間盤突出!

車禍不要緊 免費幫你治

不管別人撞你，還是你撞別人；不管你有沒有保險，出了車禍打個電話給李醫生，他會幫你把一切搞定！不用你花一分錢，全部由保險公司支付！！

腰痛、下肢痛、下肢麻木、前行困難、坐骨神經痛、頸部、肩部、上背部劇烈疼痛、手麻、手酸。采用非手術治療，運用推拿、器材和營養相搭配的方法治療腰椎、頸椎間盤突出非常有效，病人無痛苦、不用專門請假，可以邊工作邊治療，整個療程的費用比手術治療時的copay還低！！根據電腦診斷的結果針對受損的那一節椎間盤治療，準確！見效快！！一次治療下來疼痛馬上減輕80%！

李醫生治療椎間盤突出有20多年的經驗，畢業於加州大學聖荷西分校，行醫多年，信譽卓著。**獨家牽引療法有奇效！**

李醫生還專精車禍後的複健，車禍後PI與PIP都收。中文護士

Texas Spinal care 診療時間：週一、三、五 (8am-6pm) 二、四、六 (上午)

電話：713-278-2225 網址：<http://www.txspinalcare.com>

診所地址：2600 S Gessner RD, Suite 120, Houston, TX 77063

張鈞甯

張震為程偉豪挑戰演出《緝魂》



由《目擊者》、《紅衣小女孩》系列億萬票房導演程偉豪執導，張震、張鈞甯所主演的犯罪懸疑鉅作《緝魂》，即將於本週五1月29日全台盛大上映。寒假期間第一檔重量級國片《緝魂》，今(28)日舉辦電影首映會，監製唐在揚、導演程偉豪率領重量級男主角張震、新生代演員林暉閔帥氣出席，女主角張鈞甯因尚處自主隔離階段，對於無法出席首映會感到扼腕，但她也現場視訊受訪，並隔空送上紅色捲軸祝「緝魂大賣」！為戲瘦身12公斤的張震表示自己很喜歡《緝魂》劇本，願意接受挑戰的唯一理由是：「我是導演的小粉絲！」導演程偉豪直說可以讓張震答應演出簡直「美夢成真」！而新生代

演員林暉閔則是在一場森林裡的攻擊戲中，赤腳踢到現場硬物，當場腳指甲整片掀開爆血，止血後的林暉閔卻堅持把戲拍完，讓導演程偉豪大呼：「真是太拼命了！」

過年檔犯罪驚悚首選的國片《緝魂》今日盛大舉辦電影首映會，由監製唐在揚、導演程偉豪率領重量級男主角張震、新生代演員林暉閔連袂出席，這是導演程偉豪睽違三年的長片作品，挑戰國片少見的近未來、軟科幻又融合靈異懸疑等題材，也滿足了他一心想嘗試混合類型電影的願望。男主角張震在《緝魂》中為飾演罹癌病患，不僅減重12公斤、剃光頭造型，在片中他更一反陽剛帥氣形象，展現衰弱的病容

樣貌，被外界視為是他「從影以來最大犧牲」！張震表示，他會接演《緝魂》除了想挑戰自己的極限外，他更是對導演程偉豪充滿信心：「我是導演的小粉絲，相信他會將我喜歡的劇本拍得很好！」會後將進影廳首度觀看《緝魂》的張震，也深表興奮：「很期待也很緊張自己的演出！」而尚處於自主隔離階段的張鈞甯，也接受現場視訊連線訪問，談及《緝魂》中一場與張震激動爭執的戲碼，兩人演技大爆發，不僅現場痛哭到張鈞甯直呼「心很痛」，導演程偉豪看剪接時更是多次落淚，兩人自然互動也讓張震極為印象深刻。即將隔離出關的張鈞甯，也隔空送上紅色捲軸給四位主創預祝「緝魂大賣」

，更期待之後她和其他演員合體的宣傳活動。

近來備受矚目的林暉閔，則在《緝魂》中吃盡苦頭，不僅拍戲前要畫上長達五六小時的全身刺青，還有一場狂挨巴掌戲被打到頭暈臉腫，更在一場小木屋的攻擊戲中，他赤腳踢到硬物，當場腳指甲整片脫落爆血，花了一年多時間才長回來。聊到這場戲，林暉閔回憶意外發生當下劇組人員都嚇呆，趕緊將他送急診，但他堅持止血後繼續回片場把戲拍完：「我不希望耽誤到劇組的進度，所以一心只想趕快拍完，也顧不了有多痛。」他的拼命程度也讓導演程偉豪直呼：「果然是年輕人！」而導演程偉豪也呼籲看完電影的觀眾務必保密，更

強調《緝魂》不但具有《目擊者》的懸疑驚悚，更有《紅衣小女孩》系列的靈異詭譎，保證讓台灣觀眾耳目一新！

著名集團董事長慘死家中，負責此案的檢察官梁文超（張震 飾）與妻子刑警阿爆（張鈞甯 飾）在調查過程中得知，死者多年的合作夥伴萬博士（李銘順 飾）、與前妻的兒子王天佑（林暉閔 飾）、年輕的新婚妻子李燕（孫安可 飾），甚至是死去的前妻，每個嫌疑人之間都有著錯綜複雜的關聯，隨著更多線索逐漸浮出水面，他們也逐漸發現了豪門血案背後隱藏的驚人秘密……。《緝魂》於1月29日全台重磅上映，更多電影資訊歡迎上官方微博查詢。

《複身犯》楊祐寧切換人格 王淨要傲嬌最難揣摩



犯罪懸疑鉅作《複身犯》以「腦意識上傳」為電影主軸，今日（28日）發佈正式海報和最新花絮，男主角楊祐寧高難度演出「後天」人格分裂者，除了演自己，還要揣摩陳以文、王淨、林哲熹的人格特色，聲線、語調、肢體動作都天差地別，難度最高莫過於揣摩王淨的女性姿態與傲嬌感，楊祐寧自曝常偷偷「觀察」每個人，精準捕捉他們細微的表情變化跟習慣動作。

《複身犯》描述為偵破一起兒童綁票案，楊祐寧飾演的死刑犯「193」腦內遭強行植入多位嫌疑犯的意識，成為一個借屍還魂的怪物，除了從外觀、個性來詮釋其他人格，楊祐寧更特別觀

察他們的發聲位置，由裡而外化身另一個人，飾演警探的李銘忠也直呼：「我覺得好可怕！就好像一個活生生的人，在我面前切換人格。」

最新「多重人格」花絮也透露每個嫌疑犯的人格特色，林哲熹所飾演的公車司機邱俊生，是個愛嗑檳榔又滿嘴髒話的臺客，他逗趣地說：「這次做了檳榔嘴，是很好玩的體驗！」楊祐寧在演出上，刻意強化林哲熹偏低沉的發聲位置，以及臉部肌肉的扭曲。而陳以文所飾演的廖志輝，是一位做土地交易的仲介，認為錢可以解決一切事情，楊祐寧無論說話聲調跟速度，甚至嘴角抽動幅度，都宛如陳以文上身。

楊祐寧表示，難度最高莫過於揣摩王淨所飾演的王庭，她是一名缺乏愛的少女，講話多了一點傲嬌感，跟男生比較不一樣。在聲音變化上，楊祐寧也不單單只是拉高音頻，而是從語調上加入更多女性的特徵。王淨也形容這次演出說：「每個人對於自己角色的設定，都非常不一樣，到最後反而成了一個新的火花。」

《複身犯》描述一場離奇的意外爆炸車禍，竟牽扯出駭人聽聞的連環兒童失蹤案件。警方為了追查失蹤兒童的下落，車上罹難的乘客被迫死而復生，利用意識上傳技術借屍還魂。這些人究竟是無辜的受害者？還是心懷不軌的加害者？男主角楊祐寧、女主角張榕容大飆演技，讓觀眾身歷其境，在複雜的意識空間中找出真正凶手。《複身犯》將於2月26日上映，更多詳請請上官方臉書：<https://www.facebook.com/pluralitythemovie2021>

大人瘋天竺鼠車車 小朋友迷看「屁屁偵探」 智商超越柯南與福爾摩斯



更有媒體戲稱《屁屁偵探》是給小朋友看的「燒腦懸疑之作」。此次兩集連映的《咖哩香料事件》、《瓢蟲遺蹟之謎》，前部已有讀本，但放到大螢幕上更添趣味，小朋友可以從電影版找到新謎題，互動更多；而《瓢蟲遺蹟之謎》則是改編讀本《來自遺址的求救信》，內容翻新帶來製作組的滿滿的誠意，讓小朋友在電影院目不轉睛的「找碴」，比上寒輔班更專心。

《屁屁偵探》在日本以讀本賣出亮眼成績，銷量一百五十萬本將「屁屁」威力散佈至全國，後改編成電影版在台一次上映兩集。有兒童發展醫學專家之稱的王宏哲醫師，在幼保界相當知名，許多媽媽都以他列出的書單作為買書建議，《屁屁偵探》就名列王宏哲醫師「2020年最推薦書單」其中，與《哆啦A夢科學大冒險》齊名，是他認為最適合小朋友閱讀跟學習的書目之一。

創新以互動式劇情獲得大小朋友好評的電影版《屁屁偵探》，一次兩集連映《咖哩香料事件》、《瓢蟲遺蹟之謎》，於2021年1月21日上映，為今年寒假最適合帶小朋友進戲院觀賞的作品，台北雙喜電影發行。

美南實事通

主持人：蓋軍

週二 (2/2)
7PM-8PM
本期嘉賓：

收看方式

Youtube: youtube.com/itvhouston

iTalk BB: Houston 15.3

Facebook: SCdailynews

www.scdaily.com



旅美社會觀察家

楊勁濤



德州資深律師

陳文

導演 大鵬
制片人 陈祉希
主演 王吉祥/大鵬/劉陸

吉祥如意

THE REUNIONS

1月29日
盼团圆

《吉祥如意》終極海報

1月29日講述真實春節團聚故事



海報中的唯一專業演員劉陸，影片中其他人物均由大鵬導演真實的家人出演，而電影的主人公王吉祥正是大鵬的三舅。對劉陸來說，這是首次特別的表演和拍攝經歷，“刻意的建構在真實的真相面前不堪一擊”。王吉祥及姥姥一家人在攝影機面前毫不扭捏讓演員劉陸逐漸放下了表演技巧，完成了首次浸入式的拍攝經歷。這種強烈的真實感和細節入微的家庭群像，相信也會給觀眾一種全新的觀影體驗。

首次不同尋常的春節聚會大鵬用時4年完成影片只為記錄團圓

1月27日，大鵬導演電影《吉祥如意》發布終極海報，海報內容是遊子回家開門的瞬間。該片是大鵬導演的首部現實題材影片，講述的是首位喜劇片導演突發奇想，回到東北農村老家，希望將一家人如何過年拍成一部電影，結果遭遇一系列意外。因拍電影而聚齊的家庭成員們，完成了最後的聚會。電影於2021年1月29日全國上映。

壹對十年未見的父女重遇演員劉陸搭戲大鵬家人詮釋親情故事

在今日發布的終極海報中，畫面中心是首位“女兒”手提卷春聯和紅色禮品袋，準備推開回家的門，門上還貼著大大的“福”字。雖然背後煙花燦爛，但“女兒”無法解讀的神情和畫面整體偏冷的色調，使海報呈現出與平常“過年”略有不同的冷靜氛圍。海報上的“女兒”正是影片中唯一的專業演員劉陸，她飾演的是主人公王吉祥十年未見的女兒麗麗。十年沒有回家，這個“女兒”該是以什麼樣的心情推開回家的門呢？煙火、年貨、福字這些濃烈的過年元素，與畫面偏冷色調對比鮮明地呈現出這個人物猶豫躊躇的復雜心情。

電影《吉祥如意》是大鵬導演的首部現實題材影片，影片故事源自大鵬真實經歷。除了此次

《吉祥如意》的拍攝想法起源於2016年。導演最初的想法，就是想用紀錄片的手法拍攝關於姥姥家如何過春節的劇情片。大鵬請了兩個劇組來拍攝，一個負責拍攝這場春節聚會，另一個則負責“拍攝這場拍攝”。然而拍攝過程中意外接踵而至，導演為了記錄團圓的初衷最終還是沒能完全達成，留下了遺憾，因此導演更是希望通過影片鼓勵大家，擁抱的時候好好擁抱，告別的時候好好告別。拍攝前導演的預設就是“拍場天意”，而整理素材的過程中，導演發現了種種巧合，更是印證了這場“天意”。

影片此前曾分別在上海國際電影節、北京國際電影節和中國電影金雞獎影展上進行展映。在不久前的超前點映，也獲得了觀眾一致好評，在豆瓣平臺上還獲得了8.3的高分。有豆瓣影迷表示“小時候過年坐在桌邊看大人們推杯換盞說著場面話的記憶瞬間就被喚醒了”。有人在影片中找到自己或家人的影子，也有人感受到了導演的創作初衷，“王吉祥有他的動人之處，該懂的他其實都知道。這是第一部有關親情、家庭的電影，我想導演除了想記錄，也許是希望我們能常回家看看吧。”

電影《吉祥如意》將於1月29日全國上映。雖然今年有些人還是難以踏上回家的歸程，但心在壹起，就是團圓。

《掃黑英雄》上線 高燃質感詮釋中國警察力量

由“時代楷模”楊春真實事跡改編，公安部新聞宣傳局和中國電影家協會聯合攝制，殷飛、王磊執導，唐旭、張衣、劉帥、李東翰主演的“我是警察”公安英模系列電影之《掃黑英雄》1月23日上線。目前電影已獲得多項殊榮，入選北京市廣播電視局“中國榜樣”系列網絡電影單和國家廣電總局網絡視聽節目精品工程扶持項目。

電影《掃黑英雄》塑造了壹個以胸膛堵黑惡、以脊背守民安的人民衛士形象，故事以明德市公安局副局長楊柳生命中的最後壹案為主線，講述了他在自知病情急需治療的時候，仍然選擇長期堅守在掃黑壹線，帶領整個警隊將東巖村黑惡勢力壹網打盡的故事，體現了人民警察懲奸除惡的果敢堅毅和對“朗朗乾坤清風正氣”的絕對追尋。

作為“我是警察”公安英模系列第三部電影，影片由福建省寧德市公安局蕉城分局黨委委員、副局長楊春的真實事跡改編，從警28年來，他始終以鐵壹般的理想信念奮戰在維護穩定、服務群眾第一線，2019年1月23日凌晨，因長年超負荷工作，楊春突發疾病犧牲在工作崗位上，年僅49歲。恰逢楊春同誌犧牲兩周年之際，以這位“時代楷模”為原型改編的電影《掃黑英雄》在愛奇藝視頻獨家上線，謹以此片，獻給我們的“掃黑英雄”楊春，致敬勇敢正義的人民衛士。

壹件看似意外實則蹊蹠的命案，壹場正義與邪惡的對決，抽絲剝繭，環環相扣。窮途末路的作惡匪徒，槍林彈雨的地下交易，險象環生的臥底任務……極具緊張感的動作場面壹次次沖擊著感官。整個故事的焦點放在鮮活生動的壹線掃黑幹警身上，通過專業寫實的拍攝手法，展現了壹線幹警與黑惡勢力激烈交火鬥智鬥勇的全過程。

電影中既有火熱的碰撞與冰冷的刺激，也有溫情壹片。主角楊柳在《破冰行動》中有著出色表現的實力演員唐旭飾演，他用細膩的演技塑造了壹個有血有肉的掃黑警形象。在與黑惡勢力的鬥爭中，他冷靜睿智鐵面無私，在與同事和家人的相處中，又時常展露鐵漢柔情的壹面，反差滿滿的性格特色極具人格魅力。

影片以嚴密的敘事邏輯、錯綜複雜的劇情、驚險刺激的故事情節，梳理出耐人尋味的故事脈絡，圍繞楊柳壹角鋪展開來的親情、友情、愛情、戰友情，讓人感同身受十分動容，精誠制作誠意滿滿，滿足觀眾視覺與心理的雙重觀影體驗。

黑惡不掃，社會難穩；黑惡不除，民心難安。2020年是掃黑除惡收官之年，隨著我國掃黑工作不斷取得重大突破和成果，時值掃黑除惡專項鬥爭3周年之際，《掃黑英雄》將掃黑工作的進程和力度通過影視化的方式呈現出來，讓觀眾通過電影對掃黑除惡的艱難與危險有更加直觀的了解和認識，也展示出公安民警除惡務盡、絕不手軟的決心，和對黑惡勢力零容忍的態度，彰顯公平正義。這部電影不止是壹部警匪題材的類型影片呈現，更是壹曲向觀眾傳遞“掃黑除惡人民，熱血擔當警魂”的時代英雄贊歌。

影片由北京愛奇藝科技有限公司、北京奧創世紀網絡影視發行有限公司、陝西廣電影視文化產業發展有限公司、少年派影業無錫有限公司、杭州東橋文化傳媒有限公司、北京映美時代文化傳媒有限公司、海峽西岸（北京）文化傳媒集團有限公司出品，北京慈文電影發行有限公司、北京樂娛文化傳媒有限公司、浙江柒凌年岱文化傳媒有限公司、北京環宇星華文化傳媒有限公司聯合出品。

董子健《刺殺小說家》古裝造型曝光 光影映襯少年復仇路



近日，電影《刺殺小說家》曝光了片中由董子健飾演異世界少年空文的古裝造型。影片改編自雙雪濤的同名小說，由路陽執導，寧浩監制，雷佳音、楊冪、董子健、於和偉、郭京飛和佟麗婭等領銜主演。

該片由“兩個世界”相互交織而成，父親為尋找失蹤女兒，接下刺殺小說家的任務，而同時，小說家筆下的少年復仇的奇幻世界，也正影響著現實世界。而其中，董子健飾演的小說家路空文和異世界少年空文在兩個世界遭遇追殺，現實世界的小說家能否轉危為安，異世界少年能否成功復仇，也成為影片亮點之壹。

劇照中，董子健飾演的小說家路空文搖身變為異世界少年空文。少年空文壹身短打古風裝扮，頭發散亂，眼神堅毅，極具江湖少年氣質。少年空文在叢林中縱身躍起，自在放松，雨中禦敵時卻眼神帶有銳意的殺氣，不僅有著鄉野少年的氣魄與桀驁，還有著江湖少年的清冷與肅殺之感，搭配上強烈對比的黑白光影渲染，氛圍感十足。

電影中，小說和現實，兩個世界之間奇妙的共生關係，指引著壹場“前路未卜”的復仇之旅。當赤發鬼初露端倪，全員集結開戰，董子健飾演的小說家又將如何改寫現實、拯救自我呢？期待2021大年初壹的《刺殺小說家》揭開謎底。



靚苗米 經濟，營養，美味
ECONOMICAL, NUTRITIOUS & DELICIOUS

• 家庭和飯店的首選品牌

Preferred Brand at home and in restaurants.

- 優良品質 Finest Quality
- 適用於烹飪炒飯，白飯，春捲等任何米製佳餚
Excellent for Fried Rice, Steamed Rice, Spring Rolls or any traditional rice dish.

可到您喜歡的代理分銷商處購買
Available at Your Favorite Distributor



Contact:
Phone:
E-mail:

Cesar Vazquez
713-535-8215
cvazquez@riviana.com




膝蓋酸痛 手腳麻木不用愁 何成宗醫生以幹細胞配合為您作不動刀的治療

(本報記者秦鴻鈞) 您正遭受著因為老傷、頑固性關節炎、頭痛、頸痛、腰關節痛、運動受傷、手腳麻痺、腰椎肩盤突出的種種痛苦嗎？請找何成宗醫生。

何醫生可以不用開刀，不用類固醇，他以幹細胞配合理療，絕對可以讓您在一天之內得到治療，病痛得到緩解，不浪費時間。患者的滿意度是驚人的，讓您立即重新改變人生。

要了解更多信息，請今天立即致電專業看“膝蓋”，專業看“手腳 麻木”的何成宗醫生—(713) 587-0900，(713) 777-7888



本報記者
秦鴻鈞報導



休士頓黃頁由美南新聞報業電視傳媒集團發行

2021年休士頓黃頁 已發行 美南大樓前可取



SOUTHERN NEWS GROUP

T 281-498-4310
F 281-498-2728

ad@scdaily.com
www.scdaily.com

11122 Bellaire Blvd
Houston, TX 77072